glp-1 drugs and hashimoto's GLP-1: what thyroid patients need to know before starting GLP-1 for Weight Loss and

Full escalation schedules, unit conversions, weight loss data, and switching protocols.

Yale Medicine experts explain who qualifies, who can prescribe, and what to expect.

Preclinical and initial human studies suggest that glucagon-like peptide-1 receptor agonists may be promising treatments for alcohol use disorder, but existing approved treatments should be used until safety and efficacy is demonstrated in clinical trials.

Some people covered by Medicare or Medicare Advantage now qualify for GLP-1 weight loss drugs at a lower price - $50 a month

The Phase III trial of this pipeline drug for treating type 2 diabetes mellitus, non-alcoholic fatty liver disease, and obesity started on August 28, 2023

Indication expansion, such as approvals for additional metabolic and cardiovascular conditions, is broadening patient access and driving adoption